LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Receives CE-Mark for Clinitest Rapid COVID-19 Antigen Self-Test for Unsupervised Self Testing

By LabMedica International staff writers
Posted on 05 May 2021
Print article
Image: CLINITEST Rapid COVID-19 Antigen Self-Test (Photo courtesy of Siemens Healthineers)
Image: CLINITEST Rapid COVID-19 Antigen Self-Test (Photo courtesy of Siemens Healthineers)
Siemens Healthineers’ (Erlangen, Germany) CLINITEST Rapid COVID-19 Antigen Self-Test has received CE Mark certification for unsupervised self-testing by laypersons 12 and older, including at-home testing.

The nasal swab test can be used for symptomatic or asymptomatic self-testing. For children younger than 12 years, the samples must be collected by or under supervision of an adult. The CLINITEST Rapid COVID-19 Antigen Self-Test is available in packs of one test, five tests, and 20 tests. Additionally, two configurations of the five and 20 test packages are available: a multi-use test buffer bottle, or tubes pre-filled with the test buffer solution for added convenience depending on the environment in which the test will be used.

The CLINITEST Rapid COVID-19 Antigen Self-Test has a sensitivity of 97.25% and a specificity of 100% (compared to a PCR, or nucleic acid-detection method) and provides results in 15 minutes. The simple process for collecting a nasal swab and obtaining a result are included in the Instructions for Use. A nasal swab is collected from both nostrils and then the swab is washed in a buffer to reveal a specific protein inside the SARS-CoV-2 virus. The sample is then dispensed onto the test cassette and after 15 minutes the result is visible. The position and number of lines clearly indicate whether the test is positive or negative.

“The CLINITEST Rapid COVID-19 Antigen Self-Test is among the first CE-marked tests for home use, making information about a possible infection with COVID-19 more widely available without long wait times. Siemens Healthineers has been able to offer a variety of high-quality tests to address all COVID-19 testing needs and this option makes testing even more convenient for a greater number of people," said Christoph Pedain, Head of Point of Care Diagnostics at Siemens Healthineers.


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.